Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures

por Kim, C. Kwon, Lee, Yin Rui, Ong, Lynnett, Gold, Michael, Kalali, Amir, Sarkar, Joydeep
Publicado 2022

Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial

por Gharabawi, Georges M, Greenspan, Andrew, Rupnow, Marcia FT, Kosik-Gonzalez, Colette, Bossie, Cynthia A, Zhu, Young, Kalali, Amir H, Awad, A George
Publicado 2006

What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?

por Kemp, Aaron S., Schooler, Nina R., Kalali, Amir H., Alphs, Larry, Anand, Ravi, Awad, George, Davidson, Michael, Dubé, Sanjay, Ereshefsky, Larry, Gharabawi, Georges, Leon, Andrew C., Lepine, Jean-Pierre, Potkin, Steven G., Vermeulen, An
Publicado 2010